Credit Suisse AG Lowers Position in Anavex Life Sciences Corp. (AVXL)

Credit Suisse AG trimmed its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 17.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,492 shares of the biotechnology company’s stock after selling 8,512 shares during the period. Credit Suisse AG owned 0.10% of Anavex Life Sciences Corp. worth $233,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in AVXL. Bank of New York Mellon Corp boosted its position in Anavex Life Sciences Corp. by 5.5% during the 1st quarter. Bank of New York Mellon Corp now owns 111,880 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 5,826 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of Anavex Life Sciences Corp. in the 1st quarter valued at about $105,000. American International Group Inc. raised its stake in shares of Anavex Life Sciences Corp. by 7.1% in the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,329 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Anavex Life Sciences Corp. by 13.1% in the 1st quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock valued at $8,528,000 after purchasing an additional 171,577 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Anavex Life Sciences Corp. by 16.8% in the 1st quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock valued at $1,589,000 after purchasing an additional 39,934 shares in the last quarter. 24.41% of the stock is owned by hedge funds and other institutional investors.

AVXL has been the topic of several research reports. Noble Financial reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research report on Thursday, June 8th. ValuEngine upgraded shares of Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Finally, Maxim Group set a $15.00 price objective on shares of Anavex Life Sciences Corp. and gave the company a “buy” rating in a report on Monday, May 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $11.63.

Anavex Life Sciences Corp. (NASDAQ AVXL) traded down 1.78% during midday trading on Friday, reaching $4.42. 178,178 shares of the company’s stock were exchanged. The stock’s market cap is $186.40 million. Anavex Life Sciences Corp. has a 1-year low of $2.43 and a 1-year high of $6.30. The firm’s 50-day moving average is $4.63 and its 200 day moving average is $5.34.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.09). Equities analysts anticipate that Anavex Life Sciences Corp. will post ($0.38) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Credit Suisse AG Lowers Position in Anavex Life Sciences Corp. (AVXL)” was first posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/credit-suisse-ag-has-233000-position-in-anavex-life-sciences-corp-avxl/1604055.html.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Institutional Ownership by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with our FREE daily email newsletter.

 


Latest News

New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw


Leave a Reply

 
© 2006-2017 BBNS.